| Identification | Back Directory | [Name]
5-Pyrimidinecarboxamide, N-hydroxy-2-[[2-[[6-(6-methoxy-3-pyridinyl)-4-methyl-8-quinazolinyl]oxy]ethyl]methylamino]- | [CAS]
2361418-65-5 | [Synonyms]
PI3K/HDAC-IN-2
5-Pyrimidinecarboxamide, N-hydroxy-2-[[2-[[6-(6-methoxy-3-pyridinyl)-4-methyl-8-quinazolinyl]oxy]ethyl]methylamino]- | [Molecular Formula]
C23H23N7O4 | [MOL File]
2361418-65-5.mol | [Molecular Weight]
461.48 |
| Hazard Information | Back Directory | [Uses]
PI3K/HDAC-IN-2 is a potent dual PI3K/HDAC inhibitor with IC50s of 226 nM, 279 nM, 467 nM, 29 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, respectively, and IC50s of 1.3 nM, 3.4 nM, 972 nM, 17 nM, 12 nM for HDAC1, HDAC2, HDC4, HDAC6, HDAC8, respectively. PI3K/HDAC-IN-2 exhibits PI3Kδ and class I and IIb HDAC selectivity. PI3K/HDAC-IN-2 has remarkable anticancer effects[1]. | [in vivo]
In the zebrafish xenograft model of SU-DHL-4 cells, PI3K/HDAC-IN-2 (Compound 8) exhibits in vivo growth inhibitory activity at 3 μM[1]. | [IC 50]
PI3Kα: 226 nM (IC50); PI3Kβ: 279 nM (IC50); PI3Kγ: 467 nM (IC50); PI3Kδ: 29 nM (IC50); HDAC1: 1.3 nM (IC50); HDAC2: 3.4 nM (IC50); HDAC4: 972 nM (IC50); HDAC6: 17 nM (IC50); HDAC8: 12 nM (IC50) |
|
|